Envestnet Portfolio Solutions Inc. Has $261,000 Stake in Koninklijke Philips N.V. $PHG

Envestnet Portfolio Solutions Inc. increased its holdings in shares of Koninklijke Philips N.V. (NYSE:PHG) by 18.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,879 shares of the technology company’s stock after buying an additional 1,697 shares during the period. Envestnet Portfolio Solutions Inc.’s holdings in Koninklijke Philips were worth $261,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Bessemer Group Inc. grew its holdings in Koninklijke Philips by 2,935.4% during the 1st quarter. Bessemer Group Inc. now owns 1,973 shares of the technology company’s stock worth $51,000 after acquiring an additional 1,908 shares during the period. Caitong International Asset Management Co. Ltd grew its stake in shares of Koninklijke Philips by 1,170.3% during the first quarter. Caitong International Asset Management Co. Ltd now owns 2,439 shares of the technology company’s stock worth $62,000 after purchasing an additional 2,247 shares during the period. Blue Trust Inc. increased its holdings in Koninklijke Philips by 30.0% in the second quarter. Blue Trust Inc. now owns 4,408 shares of the technology company’s stock valued at $106,000 after purchasing an additional 1,017 shares during the last quarter. Wealthquest Corp acquired a new position in Koninklijke Philips in the first quarter valued at about $116,000. Finally, Allworth Financial LP lifted its stake in Koninklijke Philips by 16.2% in the first quarter. Allworth Financial LP now owns 4,638 shares of the technology company’s stock valued at $115,000 after buying an additional 645 shares during the period. 13.67% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on PHG. Wall Street Zen lowered Koninklijke Philips from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Weiss Ratings restated a “sell (d+)” rating on shares of Koninklijke Philips in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy”.

Koninklijke Philips Trading Down 0.5%

NYSE PHG opened at $28.88 on Friday. Koninklijke Philips N.V. has a one year low of $21.48 and a one year high of $32.08. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.26 and a quick ratio of 0.81. The firm has a market cap of $27.80 billion, a P/E ratio of 151.97, a P/E/G ratio of 0.78 and a beta of 0.82. The stock’s 50-day moving average is $27.85 and its 200-day moving average is $25.55.

Koninklijke Philips (NYSE:PHG) last posted its earnings results on Tuesday, July 29th. The technology company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.29 by $0.12. The business had revenue of $5.05 billion during the quarter, compared to analysts’ expectations of $4.35 billion. Koninklijke Philips had a return on equity of 11.95% and a net margin of 1.00%. Sell-side analysts anticipate that Koninklijke Philips N.V. will post 1.63 earnings per share for the current fiscal year.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.